Overview

Corporate Presentation

Corporate Presentation - May 2024

Download Presentation

Email Alerts

Register to receive real time alerts

Sign Up

IR Contacts

Get in touch with our IR team

Contact Us

Latest Press Releases
May 9, 2024

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in...

May 7, 2024

Reaffirms guidance for the Phase 2a RIVER trial in refractory chronic cough and Human Abuse Potential (HAP) Study with topline data for each expected in the second half of 2024 Topline results...

May 1, 2024

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in...

View All Press Releases

Events

We are developing the investigational therapy Haduvio™ (oral nalbuphine ER) for patients with chronic cough in idiopathic pulmonary fibrosis (IPF), refractory chronic cough (RCC), and prurigo nodularis. Haduvio has a unique mechanism of action that targets cough centrally and peripherally and has the potential for a synergistic anti-tussive effect to treat chronic cough.

Our novel oral formulation has the potential to unlock new market opportunities and significantly improve the quality of life of chronic cough patients who currently have few treatment options.

Explore Our Pipeline